Mechanism of Jiawei Xionggui Decoction in ameliorating cognitive impairment in APP/PS1 mice based on network pharmacology and metabolomics.
10.19540/j.cnki.cjcmm.20240902.704
- Author:
Jun-Bao XIANG
1
;
Wen WEN
1
;
Shi-Jun XU
1
Author Information
1. State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine Chengdu 610037, China School of Pharmacy, Chengdu University of Traditional Chinese Medicine Chengdu 610037, China Institute of Material Medica Integration and Transformation for Brain Disorders,Chengdu University of Traditional Chinese Medicine Chengdu 610037, China.
- Publication Type:Journal Article
- Keywords:
Alzheimer′s disease;
Jiawei Xionggui Decoction;
metabolomics;
network pharmacology
- MeSH:
Animals;
Drugs, Chinese Herbal/administration & dosage*;
Mice;
Network Pharmacology;
Metabolomics;
Cognitive Dysfunction/genetics*;
Alzheimer Disease/genetics*;
Mice, Inbred C57BL;
Amyloid beta-Protein Precursor/metabolism*;
Male;
Brain/drug effects*;
Humans;
Presenilin-1/metabolism*;
Protein Interaction Maps/drug effects*;
Mice, Transgenic;
Disease Models, Animal
- From:
China Journal of Chinese Materia Medica
2025;50(2):322-342
- CountryChina
- Language:Chinese
-
Abstract:
This study explored the action mechanism of Jiawei Xionggui Decoction in the treatment of Alzheimer's disease(AD) by integrating mouse brain tissue metabolomics and network pharmacology. Six-month-old amyloid precursor protein/presenilin 1(APP/PS1) mice were selected and divided into the APP/PS1 group and Jiawei Xionggui Decoction intervention group, with age-matched C57BL/6 mice serving as controls. Cognitive abilities and pathological damage in the mice were observed. Gas chromatography-mass spectrometry/mass spectrometry(GC-MS/MS) technology was utilized to analyze the metabolic profiles of mice brain tissue. Differential metabolites were screened, and relevant metabolic pathways were enriched. Network pharmacology was adopted to screen the active components of Jiawei Xionggui Decoction, so as to construct a protein-protein interaction network of its core targets for AD treatment and conduct Gene Ontology(GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) enrichment analysis of potential targets for Jiawei Xionggui Decoction in treating AD. Finally, a "metabolite-reaction-enzyme-gene" network was constructed for combined analysis of metabolomics and network pharmacology. The results showed that Jiawei Xionggui Decoction significantly reversed the trends of 18 differential metabolites involved in 15 metabolic pathways such as glyoxylate and dicarboxylate metabolism, glycine, serine, and threonine metabolism, pyruvate metabolism, alanine, aspartate, and glutamate metabolism, and tricarboxylic acid cycle(TCA) in mouse brain tissue. Furthermore, 383 core targets of Jiawei Xionggui Decoction were implicated in pathways like the phosphoinositide 3-kinase(PI3K)/protein kinase B(Akt) signaling pathway and calcium signaling pathway. Overall analysis indicated that energy metabolism, amino acid metabolism, and fatty acid metabolism were crucial metabolic pathways for Jiawei Xionggui Decoction in treating AD. The findings suggest that Jiawei Xionggui Decoction can protect neuronal cells in mouse brain tissue, thus improving cognitive impairment.
